1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About NovoCure Ltd

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Asaf Danziger

No 4 Grenville Street, Saint Helier JE2 4UF
Phone: 441534756700


Novocure to Report Third Quarter 2023 Financial Results
Oct 02, 2023 11:00am

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and nine months ended September 30, 2023, at 8 a.m. EDT on Thursday, October 26, 2023. To access the conference

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
Sep 29, 2023 21:00pm

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTFields) therapy, including new insights about methods to optimize TTFields intensities delivered at the target

3 Things About NovoCure That Smart Investors Know
Sep 19, 2023 14:15pm

Its cancer-treating device is struggling to find its market.

Source:The Motley Fool
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
Sep 08, 2023 20:01pm

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters exploring the use of Tumor Treating Fields (TTFields) therapy in

3 Healthcare Stocks to Sell in September Before They Crash & Burn
Sep 06, 2023 18:27pm

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and positive results for therapies, pharmaceuticals, and trials greatly influences the outlook for companies, especially ones with small market cap share price. Healthcare companies can see a massive surge in their share price, following encouraging treatment outcomes, but the reverse is also true. If results are lackluster, the stock price could plummet. It is a double-edged sword, and investors can get burned quickly if they’re not careful about investing in the biotech and pharmaceutical industry. Let’s look at three healthcare companies that investors should avoid at this time. Sage Therapeutics (SAGE) Source: Andrus Ciprian / Shutterstock.com Sage Therapeutics (NASDAQ: SAGE ) is a biopharmaceutical company that develops medicines to treat neurologic disorders of the brain. Their flagship medication Zulresso is an injection to treat postpartum depression, and their only novel therapy publicly marketed now.

Down 31% in 1 Day, What''s Next for NovoCure Stock?
Sep 04, 2023 13:30pm

It''s entering a risky period, but it could persevere.

Source:The Motley Fool
Why Novocure Stock Fell 24.4% This Week
Aug 31, 2023 22:52pm

Novocure announced a disappointing outcome from a phase 3 clinical trial for a key cancer treatment.

Source:The Motley Fool
Is NovoCure''s Stock Headed for a Free Fall?
Aug 31, 2023 13:55pm

It can be hard to find a reason to remain bullish on NovoCure.

Source:The Motley Fool
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies | NVCR Stock News
Aug 29, 2023 23:31pm

ROOT, Switzerland---- Novocure announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of

Source:Stock Titan
HC Wainwright cuts NovoCure to neutral in wake of failed study
Aug 29, 2023 20:27pm

HC Wainwright has cut its rating on NovoCure (NVCR) to neutral, citing the recent failure of company''s Phase 3 study for its therapy TTFields in treating advanced ovarian cancer.

Source:Seeking Alpha